Novartis is buying Avidity Biosciences for $12 billion, picking up RNA-based medicines for neuromuscular diseases as it seeks ...
Since interagency cooperation isn’t succeeding organically, it’s time for top-down initiatives led by a Health and Human ...
Researchers worry that Medicaid home care eligibility decisions are often made without public scrutiny and based less on ...
Sometimes the biggest moments at a conference happen backstage. At the annual STAT Summit, that kind of moment involved a ...
Submit a response to a recent First Opinion essay below. Selected submissions will appear in our weekly letter to the editor roundup, published every Saturday.
Advocacy groups form a buyer’s club to obtain generic versions of pricey Vertex cystic fibrosis drug
Frustrated by the price of a lifesaving cystic fibrosis treatment sold by Vertex Pharmaceuticals, a group of families is ...
The Food and Drug Administration on Thursday delivered a split decision on a blood cancer drug from GSK, approving its use in ...
Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.
More than 420 anti-science bills attacking longstanding public health protections have been introduced in statehouses across ...
WASHINGTON — The Trump administration’s push to make in vitro fertilization more affordable is changing the outlook and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback